Key Influencer Targeting
One of the top 20 pharmaceutical manufacturers needed to map the impact of Key Influencers on the treatment behavior of non-influencers, including identifying Regional Key Influencers. This mapping will focus on recognizing “high impact” Key Influencers with significant influence over the real-world treatment decisions made by various patient groups in academic and community-based healthcare facilities. […]
Predicting Patient Switching
A large pharmaceutical manufacturer ranked within the top 20, recognizes that the increasing approval of therapies in recent years poses a challenge. Shifting away from their established standard-of-care therapy may result in a reduction in the utilization of their brand. Would you like to learn more about our approach to predicting drivers of patient switching […]
Patient Finder
Product Y can extend the lifespan of patients when used early in the disease progression. However, it treats a rare condition that healthcare providers (HCPs) encounter infrequently, often resulting in delayed treatment until patients exhibit symptoms in later stages. Would you like to learn more about our approach to finding these potential patients to treat […]
Concomitant Drug Usage Analysis
A large pharma client sought a comprehensive analysis of any potential side effects or co-morbidities that may arise from their product. In addition to this analysis, they were also interested in learning how their brand compares to their competitors. Are you interested in learning more about our team’s approach in this scenario?
Lab Alert Analysis
A small-to-medium sized Biopharma company with a recently launched product in the Oncology space wanted to expand their eligible patient population by driving the adoption of appropriate biomarker testing – i.e., having more patients tested at the right time with the right type of test and via the right testing channels. Would you like to […]
Principal Investigator Targeting
A pharmaceutical company spent 24 months trying to recruit patients for a phase III clinical trial (TRIAL A). However, at the end of this period, they had only managed to enroll 20% of the patients required by the FDA.Would you like to learn more about our approach to accelerating patient enrollment for clinical trials?
